What the trial was testing
The TENAYA enrolled 671 patients with macular degeneration. The study was sponsored by Hoffmann-La Roche and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
~45% of faricimab patients only needed an injection every 16 weeks at one year.
The Lancet · 2022 · NCT03823287
These findings — that on faricimab were able to extend injections to every 16 weeks at one year — were published in the The Lancet and represent the headline result of the study.
Researchers tracked outcomes across 671 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with macular degeneration, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Faricimab (Vabysmo) is FDA-approved for wet macular degeneration and available now. The big patient win is fewer trips for injections — many people can stretch to every 4 months once stable. Ask your retina specialist whether faricimab fits your treatment plan, especially if you're tired of monthly visits.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open macular degeneration trials
Analysis of Biomarkers From Patients With Chorioretinal Diseases
This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma
The goal of this clinical trial is to learn if education about additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies will improve medication management skills. The main questions it aims to answer are: Does additional task lighting, enhanced contrast, enlarged print instructions, smart apps and organizational strategies improve medication management skills, reduce errors and improve functional use of remaining vision for this task? Participants will: Oftentimes, the client is unaware of these strategies which may improve occupational performance during a valued activity. Clients with AMD, DR or Glaucoma who choose to receive the one hour OT service will be provided with 1:1 education regarding the devices and strategies that may improve their ability to perform medication management skills.